Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Cardiol Therapeutics (CRDL) EPS (Weighted Average and Diluted) (2022 - 2025)

Cardiol Therapeutics filings provide 1 years of EPS (Weighted Average and Diluted) readings, the most recent being -$0.14 for Q4 2022.

  • On a quarterly basis, EPS (Weighted Average and Diluted) changed N/A to -$0.14 in Q4 2022 year-over-year; TTM through Dec 2022 was -$0.14, a 77.11% increase, with the full-year FY2025 number at -$0.28, up 25.07% from a year prior.
  • EPS (Weighted Average and Diluted) hit -$0.14 in Q4 2022 for Cardiol Therapeutics.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of -$0.14 in Q4 2022 to a low of -$0.14 in Q4 2022.